Pharmaceuticals Acquisitions in Texas

BPGC Management LP, Spinnaker International LLC and R Investments acquired a 70% controlling interest in Nurse Assist LLC, the maker of the Stericare Solutions brand, a specialty manufacturer of medical-grade saline and sterile water products. The investor group said it plans to support management to expand the company's in‑house water purification capabilities, broaden product categories and pursue growth initiatives including potential acquisitions.

An investor consortium led by Signet Healthcare Partners with Bionpharma, Inc. and GMS Capital Partners formed Pharma Nobis, LLC to acquire Fagron's U.S. contract manufacturing business and manufacturing facility in Texarkana, Texas. Fagron will retain a 20% interest in the new company; Todd Daviau was named CEO and the investors said they will seek to grow the contract manufacturing and private-label capabilities for consumer healthcare and retail customers.

Alora Pharmaceuticals' wholly owned subsidiary, Sovereign Pharmaceuticals, acquired substantially all manufacturing capabilities of Monarch PCM, LLC in Fort Worth, Texas through bankruptcy proceedings, closing on January 4, 2022. The deal adds 60,000 sq. ft. of manufacturing space and approximately 48 employees, expanding Sovereign's solid, semi-solid and liquid pharmaceutical manufacturing capacity.

Santen Pharmaceutical Co., Ltd., through its U.S. subsidiary Santen Holdings U.S. Inc., acquired all outstanding shares of Eyevance Pharmaceuticals Holdings Inc. for $225 million in cash. The deal brings Eyevance’s topical ophthalmic product portfolio and U.S. commercial team into Santen’s global ophthalmology business; two development-stage assets (VISOVANQ and NEXAGON) were carved out and excluded from the purchase.